Downloads
Abstract
Background: With the advent of total neoadjuvant therapy (TNT), the treatment lanscape for locally advanced rectal cancer (LARC) has changed dramatically. We conduct this research to examine the real-world efficacy and safety profile of preoperative chemoradiation as a part of TNT for LARC at Ho Chi Minh City Oncology Hospital.
Methods: Interventional study on stage II - III rectal cancer patients admitted to Radiation Department of General cancer in Ho Chi Minh City oncology hospital from 1/6/2023 to 1/6/2024.
Results: From 1/6/2023 to 30/4/2024, 53 patients met the studied criteria. Median age was 58, most patients were male 62.3% and had ECOG = 0 (98.1%). Middle and low rectal cancer are the most prominent (81.1%) and 92.5% patients are at stage III according to AJCC 8th. Pelvic MRI shows that the rate of MRF (+) and EMVI (+) are 37.7% and 24.5% respectively. Only 4 patients (7.5%) progressed after preoperative chemoradiation, the rate of stable disease and partial response are 22.6% and 69.8%. Furthermore, downstaging in clinical AJCC diagnosis, clinical T, clinical N are 81.1%, 47.2% and 53.6%, respectively. All adverse events were grade 1, including abdominal/rectal pain (20.7%), diarrhoea (15.1%), fatigue (7.54%), transaminitis (3.6%), rectal bleeding (1.8%).
Conclusions: Preoperative chemoradiation is still a cornerstone of treating locally advanced rectal cancer with good disease control rate and tolerability.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
Sauer R, Fietkau R, Wittekind C, Rödel C, Martus P, Hohenberger W, et al. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. Colorectal Dis. 2003;5(5):406-15.
Schmoll HJ, Stein A, Van Cutsem E, Price T, Hofheinz RD, Nordlinger B, et al. Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. J Clin Oncol. 2021;39(1):17-29.
Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29-42.
Conroy T, Etienne P-L, Rio E, Evesque L, MesgouezNebout N, Vendrely V, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER
GI trial. Journal of Clinical Oncology. 2023;41(17_suppl):LBA3504-LBA3504.
Liu S, Jiang T, Xiao L, Yang S, Liu Q, Gao Y, et al. Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. Oncologist. 2021;26(9):e1555-e1566.
Daprà V, Airoldi M, Bartolini M, Fazio R, Mondello G, Tronconi MC, et al. Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand? 2023;24(15):12159.
Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, et al. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial. Ann Surg. 2023;278(4):e766-e772.
| Published | 23-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 6 (2024) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.16.6.1 | |
| Keywords | Ung thư trực tràng tiến xa tại chỗ tại vùng, liệu pháp tân bổ trợ toàn diện, hóa xạ trị đồng thời tiêu chuẩn trước mổ, dữ liệu đời thực. Locally advanced rectal cancer, preoperative chemoradiation, long course chemoradiation, real-world data |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Journal of Clinical Medicine Hue Central Hospital